Zobrazeno 1 - 10
of 156
pro vyhledávání: '"bispecific antibody (BsAb)"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) is an aggressive disease with poor prognosis and limited therapeutic options. High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHCT) was historically th
Externí odkaz:
https://doaj.org/article/e626138fcfab4fad9089359115afeea4
Autor:
Huei-Jen Chen, Yi-An Cheng, Yu-Tung Chen, Chia-Ching Li, Bo-Cheng Huang, Shih-Ting Hong, I.-Ju Chen, Kai-Wen Ho, Chiao-Yun Chen, Fang-Ming Chen, Jaw-Yuan Wang, Steve R. Roffler, Tian-Lu Cheng, Tung-Ho Wu
Publikováno v:
Cancer Nanotechnology, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract Background PEGylated nanoparticles (PEG-NPs) are not effective for hematologic malignancies as they lack the enhanced permeability and retention effect (EPR effect). Tumor-targeted PEG-NPs can systemically track lymphoma and actively interna
Externí odkaz:
https://doaj.org/article/d7e948b59260455786e1f5ea63ad1238
Autor:
Hong Zhang, Qun Wang, Sireesha Yalavarthi, Lukas Pekar, Steven Shamnoski, Liufang Hu, Laura Helming, Stefan Zielonka, Chunxiao Xu
Publikováno v:
Cancer Treatment and Research Communications, Vol 39, Iss , Pp 100805- (2024)
Background: Targeting the costimulatory receptor CD137 has shown promise as a therapeutic approach for cancer immunotherapy, resulting in anti-tumor efficacy demonstrated in clinical trials. However, the initial CD137 agonistic antibodies, urelumab a
Externí odkaz:
https://doaj.org/article/e621193e51474f58b0dcc705449c666d
Autor:
Yi-Jou Chen, Michael Chen, Tian-Lu Cheng, Yi-Shan Tsai, Chang-Hung Wang, Che-Yi Chen, Tung-Yun Wu, Shey-Cherng Tzou, Kai-Hung Wang, Jing-Jy Cheng, An-Pei Kao, Shyr-Yi Lin, Kuo-Hsiang Chuang
Publikováno v:
Journal of Biomedical Science, Vol 30, Iss 1, Pp 1-19 (2023)
Abstract Background Cancer-specific adoptive T cell therapy has achieved successful milestones in multiple clinical treatments. However, the commercial production of cancer-specific T cells is often hampered by laborious cell culture procedures, the
Externí odkaz:
https://doaj.org/article/3306fd61a6ee4e49b2484aa0cb693348
Autor:
Weijie Cao, Haizhou Xing, Yingmei Li, Wenliang Tian, Yongping Song, Zhongxing Jiang, Jifeng Yu
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-21 (2022)
Abstract The claudin18.2 (CLDN18.2) protein, an isoform of claudin18, a member of the tight junction protein family, is a highly selective biomarker with limited expression in normal tissues and often abnormal expression during the occurrence and dev
Externí odkaz:
https://doaj.org/article/4756df64263541f5abcf0d780968342c
Autor:
Yordkhwan W. Iwasaki, Kannan Tharakaraman, Vidya Subramanian, Amnart Khongmanee, Andrew Hatas, Eduardo Fleischer, Troy T. Rurak, Patchara Ngok-ngam, Phanthakarn Tit-oon, Mathuros Ruchirawat, Jutamaad Satayavivad, Mayuree Fuangthong, Ram Sasisekharan
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
Bispecific antibodies (BsAbs) form an exciting class of bio-therapeutics owing to their multispecificity. Although numerous formats have been developed, generation of hetero-tetrameric IgG1-like BsAbs having acceptable safety and pharmacokinetics pro
Externí odkaz:
https://doaj.org/article/0b05f98023ee4509875b0b2c461a97c0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Justin Watts, Tara L. Lin, Alice Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul Shami, Elizabeth Cull, Christopher R. Cogle, Eunice Wang, Fatih M. Uckun
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
APVO436 is a recombinant bispecific antibody designed to direct host cytotoxic T-cells to CD123-expressing blast cells in patients with hematologic malignancies. APVO436 showed promising tolerability and single-agent activity in relapsed or refractor
Externí odkaz:
https://doaj.org/article/428b3dd5b7034e30953581d8a30b3ea9